Clinical Trial Update: Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial exploring whether mutation scores and differential protein markers can predict the efficacy of adjuvant chemotherapy in HER2-negative luminal B br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Luminal Breast Cancer

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Susceptibility, Genetic, Chemotherapy Effect | Phase 3 | Status: UNKNOWN